10/ 075,073

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 43	Jun 06	PASCAL enhanced with additional data

10/ 075,073

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:39:23 ON 07 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:39:37 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 JUN 2003  HIGHEST RN 526915-11-7
DICTIONARY FILE UPDATES:    6 JUN 2003  HIGHEST RN 526915-11-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10075073.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```

10/ 075,073



G1 O,S

G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=>
Uploading 10075073a.str

L2 STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2 STR



G1 O,S

G2 C,O,S,N

G3 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 10:41:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 161203 TO ITERATE

10/ 075,073

100.0% PROCESSED 161203 ITERATIONS 39245 ANSWERS
SEARCH TIME: 00.00.02

L3 39245 SEA SSS FUL L1

=> s l2 ful
FULL SEARCH INITIATED 10:41:25 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17991 TO ITERATE

100.0% PROCESSED 17991 ITERATIONS 2845 ANSWERS
SEARCH TIME: 00.00.01

L4 2845 SEA SSS FUL L2

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 297.90 298.11

FILE 'CAPLUS' ENTERED AT 10:42:59 ON 07 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Jun 2003 VOL 138 ISS 24
FILE LAST UPDATED: 6 Jun 2003 (20030606/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L5 55566 L3

=> s l4
L6 306 L4

=> s l3/biol
55566 L3
5427635 BIOL/RL
L7 34683 L3/BIOL
(L3 (L) BIOL/RL)

=> s l4/biol
306 L4
5427635 BIOL/RL
L8 90 L4/BIOL
(L4 (L) BIOL/RL)

=> d l8 1- ibib abs fhitstr
YOU HAVE REQUESTED DATA FROM 90 ANSWERS - CONTINUE? Y/(N):y

10/ 075,073

L8 ANSWER 1 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:117829 CAPLUS
DOCUMENT NUMBER: 138:153549
TITLE: Preparation of thieno[2,3-d]pyrimidinediones and their use in the modulation of autoimmune disease
INVENTOR(S): Reynolds, Rachel Heulwen; Ingall, Anthony Howard; Rasul, Rukhsana Tasneem; Guile, Simon David; Cooper, Martin Edward
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011868	A1	20030213	WO 2002-GB3399	20020724

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-18479 A 20010728
late
OTHER SOURCE(S): MARPAT 138:153549
GI



I

AB The invention relates to thieno[2,3-d]pyrimidinediones (shown as I; variables defined below; e.g. (S)-5-(4-hydroxyisoxazolidin-2-ylcarbonyl)-3-methyl-1-(isobutyl)-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione), methods of prepg., pharmaceutical compns. contg. and methods of using I, particularly in the modulation of autoimmune disease. For I: R1 and R2 = C1-6 alkyl, C3-6 alkenyl, C3-6 cycloalkyl C1-3 alkyl or C3-6 cycloalkyl; each of which may be optionally substituted by 1 to 3 halogen atoms; R3 = isoxazolidin-2-ylcarbonyl or tetrahydroisoxazin-2-ylcarbonyl wherein each ring is optionally substituted by one hydroxy group; Q is CO- or C(R4)(R5)- (wherein R4 is H or C1-4 alkyl and R5 is H or hydroxy group); Ar = 5- to 10-membered arom. ring system wherein up to 4 ring atoms may be heteroatoms = N, O and S, the ring system being optionally substituted by .gtoreq.1 substituents as defined in the specification. In tests of inhibition of phorbol myristate acetate

10/ 075,073

(PMA)/ionomycin-stimulated peripheral blood mononuclear cell proliferation, IA50 values for I were < 1 .times. 10-6 M; e.g. 1.7 .times. 10-10 M for (S)-5-(4-hydroxyisoxazolidin-2-ylcarbonyl)-3-methyl-1-(isobutyl)-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione and 5 .times. 10-9 for (S)-5-(4-hydroxyisoxazolidin-2-ylcarbonyl)-3-methyl-1-(isopropyl)-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione. More than 40 examples of prepn. of I are included. For example, 136 mg of (S)-5-(4-hydroxyisoxazolidin-2-ylcarbonyl)-3-methyl-1-(isobutyl)-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione was prepd. by adding to a suspension of sodium 1,2,3,4-tetrahydro-3-methyl-1-(isobutyl)-2,4-dioxo-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-5-carboxylate (157 mg) in CH2Cl2 (5 mL) 1-hydroxybenzotriazole hydrate (108 mg), stirring the mixt. for 15 min, adding 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (135 mg), stirring for 1 h, adding (S)-4-isoxazolidinol hydrochloride (69 mg) and NEt3 (147 .mu.L), stirring the reaction mixt. for 18 h concg. under reduced pressure, and purifying by column chromatog. Prepn. of reactant sodium 1,2,3,4-tetrahydro-3-methyl-1-(isobutyl)-2,4-dioxo-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-5-carboxylate from N-hydroxyphthalimide and (R)-(+)-epichlorohydrin via intermediates 2-(4-hydroxyisoxazolidin-2-yl)carbonylbenzoate, (S)-4-isoxazolidinol hydrochloride, Et 1,2,3,4-tetrahydro-3-methyl-1-(isobutyl)-2,4-dioxothieno[2,3-d]pyrimidine-5-carboxylate, 1,2,3,4-tetrahydro-6-[hydroxy(4-quinolinyl)methyl]-3-methyl-1-(isobutyl)-2,4-dioxothieno[2,3-d]pyrimidine-5-carboxylate and 1,2,3,4-tetrahydro-3-methyl-1-(isobutyl)-2,4-dioxo-6-(4-quinolinylmethyl)thieno[2,3-d]pyrimidine-5-carboxylate are also described.

IT **496791-37-8P**, (S)-6-[(3,5-Dimethyl-1H-pyrazol-4-yl)methyl]-5-[(4-hydroxyisoxazolidin-2-yl)carbonyl]-1-isobutyl-3-methylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; prepn. of thienopyrimidinediones and their use in modulation of autoimmune diseases)

RN 496791-37-8 CAPLUS

CN 4-Isoxazolidinol, 2-[[6-[(3,5-dimethyl-1H-pyrazol-4-yl)methyl]-1,2,3,4-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxothieno[2,3-d]pyrimidin-5-yl]carbonyl]-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2003:76788 CAPLUS
DOCUMENT NUMBER: 138:122656

10/ 075,073

TITLE: Preparation of thieno[2,3-d]pyrimidinediones as immunosuppressants for treatment of obstructive airway disease
INVENTOR(S): Reynolds, Rachel Heulwen; Ingall, Anthony Howard
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008422	A1	20030130	WO 2002-GB3250	20020716

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2001-17583 A 20010719
OTHER SOURCE(S): MARPAT 138:122656
GI



I



II

AB Title compds. I [wherein R1 and R2 = independently (halo)alkyl, (halo)alkenyl, or (halo)cycloalkyl(alkyl); R3 = CONR10YR11 or SO2NR10YR11; Y = O, S, or NR12; R10 and R11 = independently (un)substituted alkyl; R12 = H or alkyl; Q = CO or CR4R5; R4 = H or alkyl; R5 = H or OH; Ar = (un)substituted 5-10 membered (hetero)arom. ring; or pharmaceutically acceptable salts or prodrugs thereof] were prepd. as T cell proliferation inhibitors. For example, 6-mercapto-3-methyl-1-(2-methylpropyl)pyrimidine-2,4(1H,3H)-dione was reacted with Et bromopyruvate in the presence of K2CO3 to give Et 1,2,3,4-tetrahydro-3-methyl-1-(2-methylpropyl)-2,4-dioxothieno[2,3-d]pyrimidine-5-carboxylate. Treatment with lithium diisopropylamide in THF and addn. of 4-quinolinecarboxaldehyde afforded 6-substituted thienopyrimidinedione. Redn. with trifluoroacetic anhydride, sapon. with 1M NaOH, and amidation with N,O-dimethylhydroxylamine.bul.HCl provided II. In a phorbol 12-myristate 13-acetate (PMA)/ionomycin-stimulated peripheral blood mononuclear cell

(PBMC) proliferation assay, the latter exhibited an IA50 of 5.88 x 10-9 M. I are useful as immunosuppressants for treatment of obstructive airway disease and other autoimmune diseases.

IT **491615-50-0P**, Methyl 4-[[1,2,3,4-tetrahydro-5-[(N-methoxy-N-methylamino)carbonyl]-3-methyl-1-(2-methylpropyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl](hydroxy)methyl]-1-methyl-1H-pyrrole-2-carboxylate
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(immunosuppressant; prepn. of thieno[2,3-d]pyrimidinedione immunosuppressants by reacting mercaptopyrimidinediones with bromopyruvates or bromooxobutanoates)

RN 491615-50-0 CAPLUS

CN 1H-Pyrrole-2-carboxylic acid, 4-[hydroxy[1,2,3,4-tetrahydro-5-[(methoxymethylamino)carbonyl]-3-methyl-1-(2-methylpropyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]methyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2003:13467 CAPLUS

DOCUMENT NUMBER: 138:184210

TITLE: Rigidins B-D, new pyrrolopyrimidine alkaloids from a tunicate Cystodytes species

AUTHOR(S): Tsuda, Masashi; Nozawa, Kohei; Shimbo, Kazutaka; Kobayashi, Jun'ichi

CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, 060-0812, Japan

SOURCE: Journal of Natural Products (2003), 66(2), 292-294
CODEN: JNPRDF; ISSN: 0163-3864

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

10/ 075,073

AB Three new pyrrolopyrimidine alkaloids, rigidins B-D (e.g. I, rigidin B), have been isolated from an Okinawan marine tunicate Cystodytes sp., and the structures were elucidated on the basis of spectroscopic data.

IT **132160-44-2**, Rigidin
RL: BSU (Biological study, unclassified); **BIOL (Biological study)** ; **BIOL (Biological study)**
(pyrrolopyrimidine alkaloids from tunicate Cystodytes species)

RN 132160-44-2 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 6-(4-hydroxybenzoyl)-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:898393 CAPLUS

DOCUMENT NUMBER: 138:66168

TITLE: Discovery of a Thieno[2,3-d]pyrimidine-2,4-dione Bearing a p-Methoxyureidophenyl Moiety at the 6-Position: A Highly Potent and Orally Bioavailable Non-Peptide Antagonist for the Human Luteinizing Hormone-Releasing Hormone Receptor

AUTHOR(S): Sasaki, Satoshi; Cho, Nobuo; Nara, Yoshi; Harada, Masataka; Endo, Satoshi; Suzuki, Nobuhiro; Furuya, Shuichi; Fujino, Masahiko

CORPORATE SOURCE: Pharmaceutical Research Division, Takeda Chemical Industries Ltd., Ibaraki, 300-4293, Japan

SOURCE: Journal of Medicinal Chemistry (2003), 46(1), 113-124
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

10/ 075,073

AB We have previously disclosed the first potent and orally effective non-peptide antagonist for the human LH-releasing hormone (LHRH) receptor, a thieno[2,3-b]pyridin-4-one deriv., T-98475. Extensive research on developing non-peptide LHRH antagonists has been carried out by employing a strategy of replacing the thienopyridin-4-one nucleus with other heterocyclic surrogates. We describe herein the design and synthesis of a series of thieno[2,3-d]pyrimidine-2,4-dione derivs. contg. a biaryl moiety, which led to the discovery of a highly potent and orally active non-peptide LHRH antagonist, 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (I: TAK-013). Compd. I showed high binding affinity and potent in vitro antagonistic activity for the human receptor with half-maximal inhibition concn. (IC50) values of 0.1 and 0.06 nM, resp. Oral administration of I caused almost complete suppression of the plasma LH levels in castrated male cynomolgus monkeys at a 30 mg/kg dose with sufficient duration of action (more than 24 h). The results demonstrated that the thienopyrimidine-2,4-dione core is an excellent surrogate for the thienopyridin-4-one and that thienopyrimidine-2,4-diones and thienopyridin-4-ones constitute a new class of potent and orally bioavailable LHRH receptor antagonists. Furthermore, mol. modeling studies indicate that the unique methoxyurea side chain of I preferentially forms an intramol. hydrogen bond between the aniline NH and the methoxy oxygen atom. The hydrogen bond will shield the hydrogen bonding moieties from the solvent and reduce the desolvation energy cost. It is therefore speculated that the intramol. hydrogen bond resulting from judicious incorporation of an oxygen atom into the terminal alkyl group of the urea may increase the apparent lipophilicity to allow increased membrane permeability and consequently to improve the oral absorption of I in monkeys. On the basis of its profile, compd. I has been selected as a candidate for clin. trials and it is expected that it will provide a new class of potential therapeutic agents for the clin. treatment of a variety of sex-hormone-dependent diseases.

IT **181817-21-0P**
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of methoxyureidophenyl thienopyrimidinediones as LHRH receptor antagonists)

RN 181817-21-0 CAPLUS

CN Propanamide, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]- (9CI) (CA INDEX NAME)

10/ 075,073





REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:747681 CAPLUS
DOCUMENT NUMBER: 137:273233
TITLE: PARP inhibitors for treatment of retinal degeneration or chemotherapy-induced cell injury
INVENTOR(S): Tatsuno, Toru; Ikeda, Kazuhito; Aino, Hiroshi; Ogawa, Hiroki
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002284699	A2	20021003	JP 2001-92373	20010328

PRIORITY APPLN. INFO.: JP 2001-92373 20010328
OTHER SOURCE(S): MARPAT 137:273233

AB The invention provides an agent for treatment of retinal degeneration related to visual cell degeneration or treatment of chemotherapy-induced cell injury, contg. a poly(ADP-ribose)polymerase (PARP) inhibitor. A compd. 6,7-dihydro-1H,5H-pyrid[3,2,1-ij]quinazoline-1,3(2H)-dione was prepd., and its effect on n-methyl-N-nitrosourea (MNU)-induced retinal degeneration in rats was examd.

IT **53680-91-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(PARP inhibitors for treatment of retinal degeneration or chemotherapy-induced cell injury)

RN 53680-91-4 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 1-ethyl- (9CI) (CA INDEX NAME)

10/ 075,073



L8 ANSWER 6 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:747672 CAPLUS
DOCUMENT NUMBER: 137:294965
TITLE: Medicinal composition containing aryl or heteroarylsulfonamide compounds as matrix metalloproteinase inhibitors
INVENTOR(S): Kimura, Tomio; Tamaki, Kazuhiko; Miyazaki, Shojiro; Kurakata, Shinichi; Fujiwara, Kosaku
PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 107 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002284686	A2	20021003	JP 2001-91645	20010328

PRIORITY APPLN. INFO.: JP 2001-91645 20010328
OTHER SOURCE(S): MARPAT 137:294965
GI



AB Disclosed is a medicinal compn. contg. aryl or heteroarylsulfonamide deriv. represented by the following general formula R4-M-L-SO2-N(R3)CH(AR2)COR1, pharmacol. acceptable salts, esters, or other derivs. thereof [wherein R1 = OH, (un)protected NHOH; R2 = Q, Q1; wherein X1 = O, CO2, CO-S, CO, S(O)m (m = o, 1,2), (un)satd. NH, CH2, or coh2; X2 = O, S, (un)substituted NH or CH2; X3 = N, (un)substituted CH; R3 = H, (un)substituted alkyl, cycloalkyl, alkenyl, or alkynyl; L = (un)substituted arylene or heteroarylene; M = O, S; R4 = (un)substituted lower alkyl, aryl, or heteroaryl] as the active ingredient. The medicinal compn. is useful as a matrix metalloproteinase inhibitor, in particular matrix metalloproteinase-13 (MMP-13) and/or aggrecanase inhibitor, in the prevention and/or treatment of chronic articular rheumatism, osteoarthritis, metastasis, invasion, or proliferation of cancer, or breast cancer. Thus, Mitsunobu reaction of 2-(2-hydroxyethyl)-N-methyl-N-(4-phenoxybenzenesulfonyl)glycine allyl ester and 3-(2-trimethylsilyl)ethoxymethylpyrido[2,3-d]pyrimidine-2,4-dione using Ph3P and di-Et azodicarboxylate in THF at room temp. for 1 h gave N-methyl-N-(4-phenoxybenzenesulfonyl)-2-[2-[3-(2-

10/ 075,073

trimethylsilyl)ethoxymethyl-2,4-dioxopyrido[2,3-d]pyrimidin-1-yl]ethyl]glycine allyl ester which was desilylated by treatment with CF3CO2H in CH2Cl2 at room temp. for 3 h and sapond. with a mixt. of 1 N aq. NaOH and THF at room temp. for 30 min, and acidified with 1 N aq. HCl to give N-methyl-N-(4-phenoxybenzenesulfonyl)-2-[2-(2,4-dioxopyrido[2,3-d]pyrimidin-1-yl)ethyl]glycine (I). Amidation of I with hydroxylamine using N,N'-carbonyldiimidazole in a mixt. of CH2Cl2, THF, and H2O gave N-hydroxy-N.alpha.-methyl-N.alpha.-(4-phenoxybenzenesulfonyl)-2-[2-(2,4-dioxopyrido[2,3-d]pyrimidin-1-yl)ethyl]glycinamide (II). II and N-hydroxy-N.alpha.-methyl-N.alpha.-(4-phenoxybenzenesulfonyl)-2-[2-(2,4-dioxoquinazolin-1-yl)ethyl]glycinamide showed IC50 of 0.39 and 0.36 nM, resp., against MMP-13. A powder, a granule, and a tablet formulation contg. the specific title compd. were described.

IT **464216-36-2P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of aryl or heteroarylsulfonamide derivs. as matrix metalloproteinase inhibitors and medicinal compn. contg. them)

RN 464216-36-2 CAPLUS

CN Thieno[2,3-d]pyrimidine-1(2H)-butanamide, 3,4-dihydro-N-hydroxy-5-methyl-.alpha.-[methyl[(4-phenoxyphenyl)sulfonyl]amino]-2,4-dioxo- (9CI) (CA INDEX NAME)



L8 ANSWER 7 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:637683 CAPLUS
DOCUMENT NUMBER: 137:185504
TITLE: Preparation of thieno[2,3-d]pyrimidindiones as matrix metalloproteinase inhibitors for treatment of cancer, rheumatoid arthritis, and osteoarthritis
INVENTOR(S): Harter, William Glen; Li, Jie Jack; Ortwine, Daniel Fred; Shuler, Kevon Ray; Yue, Wen-song
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 278 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

10/ 075,073

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064598	A1	20020822	WO 2002-IB204	20020118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003004172	A1	20030102	US 2002-75073	20020213

PRIORITY APPLN. INFO.: US 2001-268756P P 20010214
OTHER SOURCE(S): MARPAT 137:185504
GI

Applicant's



I



II

AB Title fused pyrimidinones I [wherein C2W = 5-membered (hetero)cyclic diradical substituted with ABR3 and optionally substituted with R2; A = CO or SO0-2; B = O or NR5; or AB = C.tplbond.C; R1, R4, and R5 = independently H, alkyl, alkenyl, alkynyl, (CH2)n-(hetero)aryl, (CH2)n-cycloalkyl, (CH2)n-heterocyclyl, or alkanoyl; R2 and R3 = independently H, alkyl, alkenyl, alkynyl CN, NO2, NR4R5, (CH2)n-cycloalkyl, or (CH2)n-(hetero)aryl; or R2 = halo; n = 0-5; or NR4R5 = (un)substituted heterocyclyl; with the proviso that R1 and R3 .noteq. both H or alkyl; or pharmaceutically acceptable salts thereof] were prepd. as matrix metalloproteinase (MMP) inhibitors, esp. as selective MMP-13 inhibitors. For example, 3-benzyl-6-chloro-1H-pyrimidine-2,4-dione was coupled with mercaptoacetic acid Et ester using Na2CO3 in EtOH (67%) and the product cyclized with POCl3 in anhyd. DMF to give 3-benzyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid Et ester (95%). Sapon. (96%) followed by esterification with benzyl alc. and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate afforded II (12%). The latter selectively inhibited the hydrolytic activity of MMP-13 (0.61 .mu.M) over MMP-1 (100 .mu.M), MMP-2 (100 .mu.M), MMP-3 (18 .mu.M), MMP-7 (100 .mu.M), MMP-9 (100 .mu.M), MMP-12 (100 .mu.M), and MMP-14 (100 .mu.M) with the indicated IC50 values. I are useful for the treatment of diseases mediated by the MMP-13 enzyme, such as cancer, rheumatoid arthritis, or osteoarthritis (no data). Formulations of I are also disclosed.

IT **448964-75-8P**, 3-Benzyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-carboxylic acid benzyl ester
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological**

10/ 075,073

study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (MMP inhibitor; prepn. of thienopyrimidinediones as MMP inhibitors for treatment of cancer, rheumatoid arthritis, and osteoarthritis)

RN 448964-75-8 CAPLUS

CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-3-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:637472 CAPLUS

DOCUMENT NUMBER: 137:201321

TITLE: Preparation of substituted isophthalic acid derivatives, multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors

INVENTOR(S): Andrianjara, Charles; Ortwine, Daniel Fred; Pavlovsky, Alexander Gregory; Roark, William Howard

PATENT ASSIGNEE(S): Warner-Lambert Company, USA

SOURCE: PCT Int. Appl., 173 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064080	A2	20020822	WO 2002-IB447	20020213
WO 2002064080	A3	20021212		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003078276	A1	20030424	US 2002-75069	20020213

PRIORITY APPLN. INFO.: US 2001-268821P P 20010214

GI



I



II



III

AB Title compds., I [R1 and R2 together may form a substituted arom. ring or a heterocyclic ring; or R2 and R3 together may form substituted heterocycle; or R1, R3, or R4 = alkyl, arylalkyl, etc.; X = C, S; Y = O, N with provision when Y = N it forms a 5-membered heterocycle with R3] and II [R5, R6 = arylalkylamine, heterocyclylalkoxy, etc.; R7 = H, MeO, NO2, etc.], are prepd. and disclosed as matrix metalloproteinase (MMP) inhibitors. Thus, III was prepd. in five steps via cyclocondensation of diethylmalonate and benzylurea with subsequent chlorination, substitution with hydrosulfide hydrate to form an in situ intermediate that was reacted with bromoacetaldehyde dimethylacetal, followed by acid catalyzed cyclization and substitution with benzylchloroformate. III was demonstrated to inhibit MMP13 with an IC50 value (in .mu.M) of 0.0230. I and II bind allosterically to the catalytic domain of MMP-13 and comprise a hydrophobic group, first and second hydrogen bond acceptors and at least one, and preferably both, of a third hydrogen bond acceptor and a second hydrophobic group. Cartesian coordinates for centroids of the above features are defined in the specification. When the ligand binds to MMP-13, the first, second and third (when present) hydrogen bond acceptors bond resp. with Thr245, Thr247 and Met 253, the first hydrophobic group locates within the S1' channel of MMP-13 and the second hydrophobic group (when present) is relatively open to solvent. The compds. specifically inhibit the matrix metalloproteinase-13 enzyme and thus are useful for treating diseases resulting from tissue breakdown, such as heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis.

IT **448964-75-8P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compd.; prepn. and pharmaceutical activity of substituted isophthalic acid derivs., multicyclic pyrimidinediones and analogs thereof as matrix metalloproteinase inhibitors)

RN 448964-75-8 CAPLUS

CN Thieno[2,3-d]pyrimidine-6-carboxylic acid, 1,2,3,4-tetrahydro-2,4-dioxo-3-(phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/ 075,073



L8 ANSWER 9 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:583531 CAPLUS
DOCUMENT NUMBER: 138:313877
TITLE: Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor-.alpha. (TNF-.alpha.) production
AUTHOR(S): Fujita, Masakazu; Hirayama, Tetsuya; Ikeda, Naoko
CORPORATE SOURCE: Pharmaceutical Research Laboratories, Nikken Chemicals Co., Ltd., Saitama-shi, Saitama, 330-0835, Japan
SOURCE: Bioorganic & Medicinal Chemistry (2002), 10(10), 3113-3122
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The design, synthesis and SAR of novel diarylthiophene derivs. were performed. These compds. were designed by structural hybridization of TNF-.alpha. prodn. inhibitors bearing 4-fluorophenyl and 4-pyridyl groups such as FR133605, FR167653 and SB210313, and 6-acetyl-3-ethoxycarbonyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine found previously by us. As a result, several compds. were more potent in vitro than FR133605 against TNF-.alpha. prodn. stimulated with lipopolysaccharide.

IT **512786-21-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(design, synthesis and bioactivities of novel diarylthiophenes as inhibitors of tumor necrosis factor-.alpha. prodn.)

RN 512786-21-9 CAPLUS
CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-ethyl-5-(4-fluorophenyl)-6-(4-pyridinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:556648 CAPLUS
DOCUMENT NUMBER: 138:147549
TITLE: Enhancement of apomorphine-induced penile erection in

10/ 075,073

the rat by a selective .alpha.1D-adrenoceptor antagonist

AUTHOR(S): Mizusawa, Hiroya; Hedlund, Petter; Sjunnesson, Johan; Brioni, Jorge D.; Sullivan, James P.; Andersson, Karl-Erik

CORPORATE SOURCE: Department of Clinical Pharmacology, University of Lund, Swed.

SOURCE: British Journal of Pharmacology (2002), 136(5), 701-708
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Nature Publishing Group

DOCUMENT TYPE: Journal

LANGUAGE: English

AB 1 Effects of A-322312 (.alpha.1B-adrenoceptor (AR) antagonist), A-119637 (.alpha.1D-AR antagonist), prazosin (non-selective .alpha.1-AR antagonist), and yohimbine (.alpha.2-AR antagonist) were studied in rat corpus cavernosum (CC) and cavernous artery (Acc) prepns. Effects of intracavernous (i.c.) or i.p. administration of .alpha.1-AR antagonists on apomorphine-induced erections were investigated. 2 A-119637 attenuated elec. induced contractions in isolated CC (-logIC50; 8.12.+-.0.15), and relaxed noradrenaline (NA)-contracted prepns. by more than 90% at 10-7 M. At the same concn., the -logEC50 value for NA in Acc was altered from 6.79.+-.0.07 to 4.86.+-.0.13. In the CC and Acc, prazosin similarly inhibited contractile responses. 3 Inhibitory effects of A-322312 (10-7 M) in elec. activated CC were 32.3.+-.5.1%, whereas no effect on concn.-response curves for NA was obsd. in the Acc. Yohimbine (10-8 M and 10-7 M), enhanced elec.-induced contractions in isolated CC by 20 to 50%. At 10-6 M, inhibitory effects of yohimbine were obtained. 4 A-119637 (0.3 .mu.mol kg-1, i.p.) tripled the no. of erections, and produced a 6 fold increase in the duration of apomorphine-induced erectile responses. A-322312, prazosin, or yohimbine did not enhance erections induced by apomorphine. None of the .alpha.1-AR antagonists significantly increased ICP upon i.c. administration. Decreases in blood pressure were seen with A-119637 and prazosin. 5 The present findings show that there is a functional predominance of the .alpha.1D-AR subtype in the rat erectile tissue, and that blockade of this receptor facilitates rat penile erection induced by a suboptimal dose of apomorphine.

IT **255713-47-4**, A 119637
RL: PAC (Pharmacological activity); **BIOL (Biological study)**
(enhancement of apomorphine-induced penile erection in the rat by a selective .alpha.1D-adrenoceptor antagonist)

RN 255713-47-4 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-5-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:465844 CAPLUS

DOCUMENT NUMBER: 137:37675

TITLE: Medicinal compositions of nonpeptidyl

10/ 075,073

gonadotropin-releasing hormone agonist or antagonist, process for producing the same and use thereof

INVENTOR(S): Suzuki, Hiroshi; Hata, Yoshio

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047722	A1	20020620	WO 2001-JP10956	20011214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002021139	A5	20020624	AU 2002-21139	20011214
JP 2002326960	A2	20021115	JP 2001-380955	20011214

PRIORITY APPLN. INFO.: JP 2000-382431 A 20001215
WO 2001-JP10956 W 20011214

OTHER SOURCE(S): MARPAT 137:37675

AB Disclosed are medicinal compns. comprising (i) a nonpeptidyl gonadotropin-releasing hormone agonist or antagonist, (ii) an org. acid or its salt, and (iii) a biodegradable polymer or its salt. These compns. can be efficiently produced, suffer from no trouble in quality control and can achieve a stable releasing speed over a long period of time, even in case where the nonpeptidyl GnRH agonist or antagonist is contained in a large amt. regardless of the soly., m.p. or crystallinity thereof. A compd. 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxy ureide)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione was prepd. and dissolved in dichloromethane with 3-hydroxy-2-naphthoic acid and polylactic acid. The soln. was poured in polyvinyl alc. soln., emulsified, and freeze-dried with mannitol to obtain a microsphere. The microsphere showed controlled-release of the compd. when s.c. administered in rats.

IT **308831-61-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(medicinal compns. contg. nonpeptidic GnRH agonists or antagonists, org. acids, and biodegradable polymers)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)

10/ 075,073





REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:428744 CAPLUS
DOCUMENT NUMBER: 137:10997
TITLE: Medicinal compositions containing water hardly-soluble nonpeptidic GnRH agonists or antagonists, and process for producing the same
INVENTOR(S): Yamagata, Yutaka; Hata, Yoshio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043766	A1	20020606	WO 2001-JP10417	20011129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002018494	A5	20020611	AU 2002-18494	20011129
JP 2003026601	A2	20030129	JP 2001-364107	20011129

PRIORITY APPLN. INFO.: JP 2000-362727 A 20001129
WO 2001-JP10417 W 20011129
OTHER SOURCE(S): MARPAT 137:10997

AB Disclosed are compns. wherein the release of a nonpeptidic GnRH agonist and antagonist having a particularly low soly. is accelerated, namely, compns. contg. a hardly water-sol. nonpeptidic gonadotropin-releasing hormone agonist or antagonist and an arom. hydroxycarboxylic acid or its salt. A compd. 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureide)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4-(1H,3H)-dione was prepd. and dissolved in dichloromethane with salicylic acid.

10/ 075,073

The soln. was poured in polyvinyl alc. soln., emulsified, and freeze-dried with mannitol to obtain a microsphere. The microsphere showed controlled-release of the compd. when s.c.administered in rats.

IT **308831-61-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(medicinal compns. contg. water hardly-sol. nonpeptidic GnRH agonists or antagonists and arom. hydroxycarboxylic acids)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:300762 CAPLUS
DOCUMENT NUMBER: 136:340688
TITLE: Preparation of thienopyrimidinediones as drugs
INVENTOR(S): Ingall, Anthony; Bantick, John; Perry, Matthew
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.
SOURCE: Brit. UK Pat. Appl., 62 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2363377	A1	20011219	GB 2000-14375	20000614

PRIORITY APPLN. INFO.: GB 2000-14375 20000614
OTHER SOURCE(S): MARPAT 136:340688
GI

10/ 075,073



I

AB Title compds. [I; R = (hetero)aroyl, (hetero)aryl(hydroxy)alkyl, etc.; R1,R2 = H or alk(en)yl; R3 = ZR10 or (hetero)aryl; R10 = (un)substituted alk(en)yl, cycloalkylcarbonyl, halobenzoyl, etc.; Z = bond or (alkyl)imino] were prepd. Thus, I (R1 = CH2CHMe2, R2 = Me)(II; R = R3 = H) was brominated and the product converted in 2 steps to II [R = CH2C6H4(CF3)-2](III; R3 = H) which was alkynylated by HC.tplbond.CCMe2OH to give III (R3 = C.tplbond.CCMe2OH). Data for biol. activity of I were given.

IT **418754-63-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thienopyrimidinediones as drugs)

RN 418754-63-9 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 5-(3-hydroxy-3-methyl-1-butynyl)-3-methyl-1-(2-methylpropyl)-6-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)





L8 ANSWER 14 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:240593 CAPLUS
DOCUMENT NUMBER: 136:268181
TITLE: Solid preparations containing a large amount of a physiologically active substance
INVENTOR(S): Nakano, Yoshinori; Yoneyama, Shuji; Ochi, Masashi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024230	A1	20020328	WO 2001-JP8264	20010921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001088102	A5	20020402	AU 2001-88102	20010921
JP 2002167327	A2	20020611	JP 2001-290149	20010921

PRIORITY APPLN. INFO.: JP 2000-289345 A 20000922
WO 2001-JP8264 W 20010921

OTHER SOURCE(S): MARPAT 136:268181

AB It is intended to provide granules contg. a large amt. of a physiol. active substance which is hardly sol. in water and highly water-repellent, and solid prepns. contg. these granules which are excellent in the disintegration properties and the elution of the physiol. active substance. Disclosed are (1) granules contg. a physiol. active substance and a cellulose-based disintegrating agent; (2) granules contg. a physiol. active substance, a cellulose-based disintegrating agent and a binder; (3) solid prepns. comprising granules (1) or (2) as described above, a cellulose-based disintegrating agent and a stearic acid-based lubricant; and (4) the solid prepns. (3) as described above which are shaped into ellipsoidal tablets. A tablet was formulated contg. 5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione (prepn. given) 100, lactose 285, starch 50, hydroxypropyl cellulose 20, Ca carmellose 40, 40 and Mg stearate 5 mg. The tablet was coated with a compn. contg. hydroxypropyl Me cellulose 17.8, titania 2, and iron oxide 0.2 mg.

IT **308831-61-0P**, 5-(N-Benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of phenylthienopyrimidinone derivs. and oral formulations contg. them)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 15 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:226638 CAPLUS
DOCUMENT NUMBER: 137:136468
TITLE: Modified purine nucleosides as dangling ends of DNA duplexes: the effect of the nucleobase polarizability on stacking interactions
AUTHOR(S): Rosemeyer, Helmut; Seela, Frank
CORPORATE SOURCE: Laboratorium fuer Organische und Bioorganische Chemie, Institut fuer Chemie, Fachbereich Biologie/Chemie, Universitaet Osnabrueck, Osnabruck, D-49069, Germany
SOURCE: Journal of the Chemical Society, Perkin Transactions 2 (2002), (4), 746-750
CODEN: JCSPGI; ISSN: 1472-779X
PUBLISHER: Royal Society of Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Base-modified nucleotide residues have been appended to the 5'-terminus of the self-complementary oligo-2'-deoxynucleotide duplex [5'-d(CGCGCG)]2 as dangling ends. Temp.-dependent UV measurements on the resulting oligomers indicate generally higher thermal stabilities (Tm) compared to that without an overhanging end. The duplex stabilization (.DELTA.Tm) was correlated with the mol. polarizability (.alpha.m) of the base of the pendant nucleoside showing that: the higher the mol. polarizability .alpha.m of a dangling nucleobase, the higher the thermal stability of the DNA duplex.

IT **96022-82-1**
RL: BSU (Biological study, unclassified); PRP (Properties); **BIOL (Biological study)**
(modified purine nucleosides as dangling ends of DNA duplexes, the effect of the nucleobase polarizability on stacking interactions)

RN 96022-82-1 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 7-(2-deoxy-.beta.-D-erythro-pentofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 16 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:172492 CAPLUS
DOCUMENT NUMBER: 136:232165
TITLE: Preparation of xanthine derivatives and analogs as cell signaling inhibitors
INVENTOR(S): Klein, J. Peter; Klaus, Stephen J.; Kumar, Anil M.; Gong, Baoqing
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 143 pp., Cont.-in-part of U. S. Ser. No. 8,020, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002028823	A1	20020307	US 1999-288556	19990409
US 6469017	B1	20021022	US 1998-8020	19980116
WO 2000061583	A1	20001019	WO 2000-US9139	20000407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1171442	A1	20020116	EP 2000-921774	20000407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541258	T2	20021203	JP 2000-610854	20000407

PRIORITY APPLN. INFO.:
US 1998-8020 B2 19980116
US 1995-483871 A2 19950607
US 1995-486264 A2 19950607
US 1999-288556 A2 19990409
WO 2000-US9139 W 20000407

OTHER SOURCE(S): MARPAT 136:232165
GI

10/ 075,073



I



II

AB Therapeutic compds. I [R1 = H, Me, (un)substituted C5-9-alkyl, C5-9-alkenyl, C5-9-alkynyl, C3-8-hydroxyalkyl, C3-8-alkoxy, C5-9-alkoxyalkyl; R2, R3 = H, halo, oxo, (un)substituted C1-20-alkyl, C1-20-hydroxyalkyl, C(1-20)thioalklyl, C1-20-alkylamino, C1-20-alkylaminoalkyl, C1-20-aminoalkyl, C1-20-aminoalkoxyalkenyl, C1-20-aminoalkoxyalkynyl, C1-20-diaminoalkyl, C1-20-triaminoalkyl, C1-20-tetraaminoalkyl, C5-15-aminotrialkoxyamino, C1-20-alkylamido, C1-20-alkylamidoalkyl, C1-20-amidoalkyl, C1-20-acetamidoalkyl, C1-20-alkenyl, C1-20-alkynyl, C3-8-alkoxyl, C1-11-alkoxyalkyl, and C1-20-dialkoxyalkyl; with the proviso that R1 .noteq. .omega.-1 secondary alc. substituted C5-8-alkyl; X, Y = NR3, R3 = C1-3-alkyl; Z = CR3, R3 = C1-3-alkyl; dashed lines are single or double bonds] pharmaceutically acceptable derivs. (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof are described. Thus, CT 7549 (II) was prepd. via redn of 1-(5-oximinohexyl)-3,7-dimethylxanthine using sodium cyanoborohydride in methanol. These novel heterocyclic compds. I having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations assocd. with disorders affected by Interleukin-12 ("IL-12") intracellular signaling, such as, for example, Th1 cell-mediated disorders.

IT **301536-59-4P**, CT 12458
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of xanthine derivs. and analogs as cell signaling inhibitors)

RN 301536-59-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 3-[(5R)-5-hydroxyhexyl]-1,5,7-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 17 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:31283 CAPLUS

DOCUMENT NUMBER: 136:107510

TITLE: Medicinal preparations for treating sex hormone-dependent diseases

INVENTOR(S): Igari, Yasutaka; Kamei, Shigeru

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

10/ 075,073

SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002144	A1	20020110	WO 2001-JP5808	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001069439	A5	20020114	AU 2001-69439	20010704
JP 2002080397	A2	20020319	JP 2001-203722	20010704
EP 1297850	A1	20030402	EP 2001-947821	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: JP 2000-208253 A 20000705
WO 2001-JP5808 W 20010704

OTHER SOURCE(S): MARPAT 136:107510

AB Disclosed are medicinal prepns. for treating sex hormone-dependent diseases which comprise a combination of a compd. having a LH-releasing hormone effect or its salt with a compd. having a LH-releasing hormone antagonism or its salt for administering the compd. having a LH-releasing hormone effect or its salt followed by the compd. having a LH-releasing hormone antagonism or its salt. By using these prepns., the concn. of a sex hormone (for example, testosterone, LH, FSH, estrogen) can be quickly recovered after the medicable period of a compd. having a LH-releasing hormone antagonism or its salt or a prepn. contg. the same (preferably a sustained-release prepn.), which makes it possible to definitely det. the drug rest period in an intermittent treatment. A sustained-release microcapsule contg. LHRH antagonist N-acetyl-D-3-(2-naphthyl)alanyl-D-3-(4-chlorophenyl)alanyl-D-3-(3-pyridyl)alanyl-Ser-N-methyltyrosyl-D-(.epsilon.-N-nicotinoyl)lysyl-Leu-(.epsilon.-N-isopropyl)lysyl-Pro-D-Ala-NH2 acetate was prepd., and administered to a rat 4 wk after administration of a LHRH agonist Leuplin to examine the blood concn. of testosterone.

IT **308831-61-0**, 5-(N-Benzyl-N-methyl-aminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)dione
RL: THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(use of LHRH agonists and antagonists for intermittent treatment of sex hormone-dependent diseases)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)

10/ 075,073





REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 18 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:2173 CAPLUS
DOCUMENT NUMBER: 136:272783
TITLE: Anti-angiogenic activity of a novel multi-substrate analogue inhibitor of thymidine phosphorylase
AUTHOR(S): Liekens, Sandra; Bilsen, Filip; De Clercq, Erik; Priego, Eva Maria; Camarasa, Maria-Jose; Perez-Perez, Maria-Jesus; Balzarini, Jan
CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.
SOURCE: FEBS Letters (2002), 510(1,2), 83-88
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 7-Deazaxanthine (7-DX) was recently identified as the first purine deriv. with pronounced inhibitory activity against Escherichia coli thymidine phosphorylase (TP) and angiogenesis. In order to 'freeze' the enzyme in an open, inactive conformation, a novel multi-substrate analog inhibitor of TP, contg. an alkyl phosphonate moiety covalently linked to 7-DX, was synthesized. The prototype compd. TP65 (9-(8-phosphonooctyl)-7-deazaxanthine) (at 250 .mu.M) completely inhibited TP-induced formation of microvascular sprouts from endothelial cell aggregates in a three-dimensional fibrin gel. In the chick chorioallantoic membrane assay, TP caused a dose-dependent stimulation of angiogenesis, which was completely inhibited by 250 nmol TP65. This dose proved to be non-toxic for the developing chick embryo. TP65 thus emerges as a potent and specific inhibitor of TP and TP-induced angiogenesis, which opens new perspectives for multi-substrate analog inhibitors of TP as potential anti-cancer agents and as inhibitors of angiogenesis and of diseases with enhanced expression of TP.

IT **39929-79-8**, 7-Deazaxanthine
RL: PAC (Pharmacological activity); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(antiangiogenic activity of a novel multi-substrate analog inhibitor of thymidine phosphorylase)
RN 39929-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (9CI) (CA INDEX NAME)

10/ 075,073



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 19 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:923639 CAPLUS
DOCUMENT NUMBER: 136:58811
TITLE: Biodegradable polymers for sustained-release compositions
INVENTOR(S): Hata, Yoshio; Yamagata, Yutaka; Igari, Yasutaka
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001095940	A1	20011220	WO 2001-JP5009	20010613
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001064264	A5	20011224	AU 2001-64264	20010613
EP 1291023	A1	20030312	EP 2001-938630	20010613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002068982	A2	20020308	JP 2001-180061	20010614

PRIORITY APPLN. INFO.: JP 2000-178534 A 20000614
WO 2001-JP5009 W 20010613

AB Disclosed are compns. contg. a nonpeptidyl physiol. active substance and a biodegradable polymer having two or more terminal carboxyl groups or its salt which have the following characteristics: (1) the content of the nonpeptidyl physiol. active substance can be elevated and the release thereof can be regulated or accelerated to thereby ensure the achievement of the pharmacol. effect; (2) in case where the nonpeptidyl physiol. active substance has s.c. irritation, it is expected that the irritation can be overcome by the terminal groups having a high acidity; and (3) having a high glass transition point and thus being highly stable. 5-(N-Benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione was prepd. and formulated with tartronic acid-terminated polylactic acid to give microcapsules.

IT **308831-61-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of thienopyrimidines and formulation with carboxy-terminated

10/ 075,073

polymers for sustained release)
RN 308831-61-0 CAPLUS
CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 20 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:904177 CAPLUS
DOCUMENT NUMBER: 136:37621
TITLE: Preparation of 6-phenylpyrrolopyrimidinedione derivatives
INVENTOR(S): Vidal Juan, Bernat; Gracia Ferrer, Jordi; Prieto Soto, Jose Manuel; Vega Noverola, Armando
PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094350	A1	20011213	WO 2001-EP6306	20010601
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1286997	A1	20030305	EP 2001-960264	20010601
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: ES 2000-1436 A 20000607
WO 2001-EP6306 W 20010601
OTHER SOURCE(S): MARPAT 136:37621

10/ 075,073

GI



I

AB 6-Phenylpyrrolopyrimidine derivs. I [-X-C-Y- represents NHC:CR6 or -X-C-Y- represents CR6:CNH], useful as selective cyclic GMP specific phosphodiesterase (PDE 5) inhibitors, were prepd. E.g., I [R1 = Me; R2 = Pr; R3 = Et; Y = CH:; X = NH; NR4R5 = 4-methylpiperazinyl] was prepd.

IT **378794-79-7P**
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of 6-phenylpyrrolopyrimidinedione derivs. as cyclic GMP specific phosphodiesterase (PDE 5) inhibitors)

RN 378794-79-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-propoxy-3-(2,3,4,7-tetrahydro-3-methyl-2,4-dioxo-1-propyl-1H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 21 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:816672 CAPLUS
DOCUMENT NUMBER: 135:357940
TITLE: Preparation of thieno[2,3-d]pyrimidinediones for treating obstructive airways disease
INVENTOR(S): Bantick, John; Ingall, Anthony; Perry, Matthew; Reynolds, Rachel
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083489	A1	20011108	WO 2001-SE907	20010426

10/ 075,073

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 2361917	A1	20011107	GB 2000-10657 20000504
EP 1280806	A1	20030205	EP 2001-926294 20010426

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:
GB 2000-10657 A 20000504
GB 2000-17795 A 20000721
WO 2001-SE907 W 20010426

OTHER SOURCE(S): MARPAT 135:357940

GI



I

AB The title compds. [I; R = COAr1, CR4R5Ar1, Ar3; Ar1 = (un)substituted 5-10 membered arom. ring system wherein up to 3 ring atoms may be heteroatoms independently selected from N, O, and S; R1, R2 = H, alkyl, alkenyl, CH2(cycloalkyl), cycloalkyl; R3 = XAr2; X = SOn, CO, CH(OH); n = 0-2; Ar2 = (un)substituted 5-6 membered arom. ring wherein up to 4 ring atoms may be heteroatoms selected from N, O, and S; R4 = H, alkyl; R5 = H, OH; Ar3 = (un)substituted acenaphthenyl, indanyl, fluorenyl; with the proviso that when X = SOn, then Ar2 does not represent pyridyl or thienyl], useful as immunosuppressants for the treatment of asthma, chronic obstructive pulmonary disease, and allograft rejection, were prepd. E.g. a 3-step synthesis of I [R = 2-F3CC6H4CH2; R1 = iso-Bu; R2 = Me; R3 = 3-furyl(hydroxy)methyl] was described. In a PMA/ionomycin-stimulated peripheral blood mononuclear cell proliferation assay, some of the compds. I exhibited IA50 of < 1x10-6 M.

IT **372162-25-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thieno[2,3-d]pyrimidinediones for treating obstructive airways disease)

RN 372162-25-9 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-methyl-1-(2-methylpropyl)-5-(1H-1,2,4-triazol-3-ylthio)-6-[2-(trifluoromethyl)benzoyl]- (9CI) (CA INDEX NAME)

10/ 075,073



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 22 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:793414 CAPLUS
DOCUMENT NUMBER: 135:348864
TITLE: Poly(ADP-ribose) polymerase inhibitors
INVENTOR(S): Ono, Yukihiro; Otani, Kenichi; Aino, Hiroshi; Saji, Ikutaro
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001302515	A2	20011031	JP 2000-116579	20000418

PRIORITY APPLN. INFO.: JP 2000-116579 20000418
OTHER SOURCE(S): MARPAT 135:348864

AB Quinazolines, indoles, and pyrrolopyrimidines are claimed as poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of various diseases including cerebral, nervous system, gastrointestinal, and eye diseases. 1-Methyl-2,4(1H,3H)-quinazolinedione, 1-(cyclopropylmethyl)-2,4(1H,3H)-quinazolinedione, 4-methyl-2(1H)-quinazolinone, 1-ethyl-1H-pyrrolo[2,3-d]-pyrimidine-2,4(3H,7H)dione, and 1-ethyl-6,7-dihydro-1H-pyrrolo[2,3-d]-pyrimidine-2,4(3H,5H)dione were in vitro tested for inhibitory activities of PARP.

IT **53680-91-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
(poly(ADP-ribose) polymerase inhibitors for treatment of various diseases)

RN 53680-91-4 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 1-ethyl- (9CI) (CA INDEX NAME)



L8 ANSWER 23 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:781118 CAPLUS
DOCUMENT NUMBER: 135:339291
TITLE: Triplex-forming oligonucleotides inhibiting ICAM-1 gene expression and their therapeutic use
INVENTOR(S): Degitz, Klaus Karl; Besch, Robert
PATENT ASSIGNEE(S): Germany
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079487	A2	20011025	WO 2001-DE1509	20010418
WO 2001079487	A3	20020620		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 10019252	A1	20011031	DE 2000-10019252	20000418

PRIORITY APPLN. INFO.: DE 2000-10019252 A 20000418

AB The invention relates to triple helix-forming oligonucleotides which become attached to double-stranded genomic ICAM-1 DNA sequences and thus inhibit transcription. The invention also relates to these oligonucleotides as therapeutic agents in the therapy or prophylaxis of ICAM-1-assocd. diseases. Thus, ICAM-1 gene expression in human A431 keratinocyte cells was inhibited by GGTTTGTTGTGTGGGT and, more efficiently, by 3-methoxypsoralen-GTTGGTGGGTTGGGGGG conjugate and irradn. with UV light.

IT **39929-79-8**, 7-Deazaxanthine
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); **BIOL (Biological study)**; OCCU (Occurrence)
(oligonucleotides contg.; triplex-forming oligonucleotides inhibiting ICAM-1 gene expression and their therapeutic use)
RN 39929-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (9CI) (CA INDEX NAME)

10/ 075,073



L8 ANSWER 24 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:780733 CAPLUS
DOCUMENT NUMBER: 135:313627
TITLE: Preventives/remedies for Alzheimer's disease
INVENTOR(S): Furuya, Shuichi; Suzuki, Nobuhiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078780	A1	20011025	WO 2001-JP3189	20010413
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001354588	A2	20011225	JP 2001-115804	20010413

PRIORITY APPLN. INFO.: JP 2000-112046 A 20000413
GI



I

AB Preventives/remedies for Alzheimer's disease contg. a compd. having GnRH antagonism have excellent effects of preventing and treating Alzheimer's disease with little toxicity. As the compd. having GnRH antagonism, compds. represented by the structural formula (I) may be cited.

IT **308831-61-0DP**, salts
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(preventives/remedies for Alzheimer's disease)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 25 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:444501 CAPLUS

DOCUMENT NUMBER: 135:56063

TITLE: Sulfonamide derivatives as matrix metalloproteinase inhibitors

INVENTOR(S): Kimura, Tomio; Miyazaki, Shojiro; Ueda, Keishi; Tanzawa, Kazuhiko; Ushiyama, Shigeru; Takasaki, Wataru

PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 120 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001163786	A2	20010619	JP 2000-297744	20000929

PRIORITY APPLN. INFO.: JP 1999-278300 A 19990930

OTHER SOURCE(S): MARPAT 135:56063

GI



I

10/ 075,073

AB The sulfonamide derivs. (I; R1 = H, NHOH; R2 = H, (substituted)alkyl, cycloalkyl, -AR6 [A = O, -S(O)m- or -n(R9)- with alkylene; R6 = other groups]; R3 = H, (substituted)-alkyl, -cycloalkyl, -alkenyl, and -alkynyl; R4 = (substituted)(hetero)arylene; R5 = (substituted)-alkyl and -(hetero)aryl) and their pharmacol. acceptable salts are claimed as matrix metalloproteinase inhibitors for treatment of arthritis, rheumatoid arthritis, cancer metastasis, and breast cancer.

IT **246263-34-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(sulfonamide derivs. as matrix metalloproteinase inhibitors)

RN 246263-34-3 CAPLUS

CN Thieno[2,3-d]pyrimidine-3(2H)-butanamide, 1,4-dihydro-N-hydroxy-5-methyl-.alpha.-[methyl[(4-phenoxyphenyl)sulfonyl]amino]-2,4-dioxo- (9CI) (CA INDEX NAME)



L8 ANSWER 26 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:334737 CAPLUS

DOCUMENT NUMBER: 135:107300

TITLE: Structure-Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole .alpha.1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia

AUTHOR(S): Meyer, Michael D.; Altenbach, Robert J.; Bai, Hao; Basha, Fatima Z.; Carroll, William A.; Kerwin, James F., Jr.; Lebold, Suzanne A.; Lee, Edmund; Pratt, John K.; Sippy, Kevin B.; Tietje, Karin; Wendt, Michael D.; Brune, Michael E.; Buckner, Steven A.; Hancock, Arthur A.; Drizin, Irene

CORPORATE SOURCE: Neurological and Urological Diseases Research Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, 60064, USA

SOURCE: Journal of Medicinal Chemistry (2001), 44(12), 1971-1985
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:107300

GI

10/ 075,073



I

AB In search of a uroselective .alpha.1A subtype selective antagonist, a novel series of 6-methoxyhexahydrobenz[e]isoindoles attached to a bicyclic heterocyclic moiety via a two-carbon linker was synthesized. It was found that in contrast to a previously described series of tricyclic heterocycles, this bicyclic series has very specific requirements for the heterocyclic attachments. The most important structural features contributing to the .alpha.1A/.alpha.1B selectivity of these compds. were identified. In vitro functional assays for the .alpha.1 adrenoceptor subtypes were used to further characterize the most selective compds., and in vivo models of vascular vs prostatic tone were used to assess uroselectivity. The quinazolinone I showed the highest degree of selectivity in the radioligand binding assays (56-fold), in the in vitro functional tests (80-fold), and for in vivo prostate selectivity (960-fold).

IT **179240-03-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent)
(prepn. and structure-activity studies of bicyclic-substituted hexahydrobenz[e]isoindole .alpha.1A adrenoceptor antagonists)

RN 179240-03-0 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[(3aR,9bR)-1,3,3a,4,5,9b-hexahydro-6-methoxy-2H-benz[e]isoindol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 27 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:321149 CAPLUS
DOCUMENT NUMBER: 135:137465
TITLE: Two Novel and Potent 3-[(o-Methoxyphenyl)piperazinylethyl]-5-phenylthieno[2,3-d]pyrimidine-2,4-diones Selective for the .alpha.1D Receptor

10/ 075,073

AUTHOR(S): Carroll, W. A.; Sippy, K. B.; Esbenshade, T. A.; Buckner, S. A.; Hancock, A. A.; Meyer, M. D.
CORPORATE SOURCE: Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, IL, 60064-6101, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(9), 1119-1121
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:137465
GI



I

AB The synthesis and in vitro characterization of A-119637 (I, R = H) and A-123189 (I, R = Me), two novel, selective and potent .alpha.1D antagonists, are described.

IT **110164-21-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(prepn. and binding to .alpha.1D receptor)

RN 110164-21-1 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 28 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:247319 CAPLUS
DOCUMENT NUMBER: 134:266102
TITLE: Preparation of phenylsulfonamide derivatives as matrix metalloproteinase 13 and aggrecanase inhibitors
INVENTOR(S): Kimura, Tomio; Tamaki, Kazuhiko; Miyazaki, Shoujiro; Kurakata, Shinichi; Fujiwara, Kosaku
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 251 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese

10/ 075,073

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023363	A1	20010405	WO 2000-JP6798	20000929
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2001163885	A2	20010619	JP 2000-297743	20000929

PRIORITY APPLN. INFO.: JP 1999-275857 A 19990929
OTHER SOURCE(S): MARPAT 134:266102
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [R4MLSO2NR3CH(AR2)COR1; wherein R1 is OH or NHOH; R2 = Q, Q1; A is alkylene which may be interrupted by an ether linkage or the like; R3 is hydrogen, alkyl, or the like; L is optionally substituted (hetero)arylene; M is oxygen or sulfur; and R4 is optionally substituted alkyl, (hetero)aryl, or the like] and pharmaceutically acceptable salts, exhibiting inhibitory activities against matrix metalloproteinase 13 and aggrecanase, are prepd. Thus, the title compd. I was prepd. and tested.

IT **332096-46-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of phenylsulfonamide derivs. as matrix metalloproteinase 13 and aggrecanase inhibitors)

RN 332096-46-5 CAPLUS
CN Thieno[2,3-d]pyrimidine-1(2H)-butanamide, 3,4-dihydro-N-hydroxy-5-methyl-.alpha.-[methyl[(4-phenoxyphenyl)sulfonyl]amino]-2,4-dioxo-, (.alpha.R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 29 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:241744 CAPLUS
DOCUMENT NUMBER: 134:252587

10/ 075,073

TITLE: Preparation of desazapurine-nucleotides and the use thereof for nucleic acid sequencing and as antiviral agents

INVENTOR(S): Seela, Frank; Muth, Heinz-Peter; Kaiser, Klaus; Bourgeois, Werner; Muhlegger, Klaus; Von Der Eltz, Herbert; Batz, Hans-Georg

PATENT ASSIGNEE(S): Roche Diagnostics G.m.b.H., Germany

SOURCE: U.S., 15 pp., Cont.-in-part of U.S. Ser. No. 179,862, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6211158	B1	20010403	US 1992-908513	19920626
DE 3739366	A1	19881027	DE 1987-3739366	19871120
ZA 8802446	A	19881228	ZA 1988-2446	19880408
DD 269854	A5	19890712	DD 1988-314564	19880408

PRIORITY APPLN. INFO.: DE 1987-3712280 A 19870410
DE 1987-3739366 A 19871120
US 1988-179862 B2 19880411

OTHER SOURCE(S): MARPAT 134:252587

GI



I

AB The present invention provides desazapurine-nucleoside derivs. of the general formula I; wherein X is a nitrogen atom or a methine radical, W is a nitrogen atom or a C-R4 radical, R1-R4 , which can be the same or different, are hydrogen or halogen atoms, hydroxyl or mercapto groups, lower alkyl, lower alkylthio, lower alkoxy, aralkyl, aralkoxy or aryloxy radicals or amino groups optionally substituted once or twice, R5 is a hydrogen atom or a hydroxyl group, R6 and R7 are each hydrogen atoms or one of them is a halogen atom or a cyano or azido group or an amino group optionally substituted once or twice, whereby one of R6 and R7 can also be a hydroxyl group when X is a methine radical and, in addn., R5 and R7 can together also represent a further valency bond between C-2' and C-3' and Y is a hydrogen atom or a mono-, di- or tri-phosphate group and the use thereof for nucleic acid sequencing and as antiviral agents. Thus, 2-amino-7-deaza-2',3'-dideoxy-9-.beta.-D-ribofuranosyl-purine-6-one was prepd. and used for nucleic acid sequencing and as antiviral agents.

10/ 075,073

Compds. I according to the present invention can also be advantageously used for DNA sequencing according to Sanger's method. The sequencing of d(G-C)-rich DNA fragments is, in particular, made difficult by the formation of secondary structures which lead to a band compression in the region of d(G-C) clusters.

IT **120552-11-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of desazapurine-nucleotides and the use thereof for nucleic acid sequencing and as antiviral agents)

RN 120552-11-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 7-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 30 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:909212 CAPLUS
DOCUMENT NUMBER: 134:56691
TITLE: Preparation of piperazinyl thienopyrimidine diones as selective .alpha.-1D adrenoceptor antagonists
INVENTOR(S): Meyer, Michael D.; Caroll, William A.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6166019	A	20001226	US 1999-351090	19990709

PRIORITY APPLN. INFO.: US 1998-92988P P 19980716
OTHER SOURCE(S): MARPAT 134:56691
GI



I



II



III

AB The title compds. [I; R1-R3 = halo, OH, NO2, etc.; n = 2-10; R4 = II (wherein U, taken together with the carbon atoms to which it is attached forms thieno ring, etc.)] and their pharmaceutically acceptable salts, which are selective alpha-1D adrenoceptor antagonists and may be useful for treating disease states such as hypertension, were prepd. E.g., a 3-step synthesis of III as methanesulfonate salt which showed Ki of 0.213 nM against .alpha.-1D binding, was given.

IT **255713-48-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of piperazinyl thienopyrimidine diones as selective .alpha.-1D adrenoceptor antagonists)

RN 255713-48-5 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-5-phenyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 255713-47-4
CMF C25 H26 N4 O3 S



CM 2

10/ 075,073

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 31 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:864913 CAPLUS
DOCUMENT NUMBER: 134:4946
TITLE: Thienopyrimidines, their production and use as gonadotropin releasing hormone antagonists
INVENTOR(S): Furuya, Shuichi; Suzuki, Nobuhiro; Choh, Nobuo; Nara, Yoshi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056739	A1	20000928	WO 2000-JP1777	20000323
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2001278884	A2	20011010	JP 2000-87051	20000323
JP 3240293	B2	20011217		
JP 2001278885	A2	20011010	JP 2000-120277	20000323
BR 2000009297	A	20011218	BR 2000-9297	20000323
EP 1163244	A1	20011219	EP 2000-911308	20000323
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6297379	B1	20011002	US 2000-530495	20000426
US 6340686	B1	20020122	US 2000-571215	20000516
NO 2001004603	A	20011126	NO 2001-4603	20010921

PRIORITY APPLN. INFO.:
JP 1999-79371 A 19990324
JP 2000-18019 A 20000125
JP 2000-87051 A3 20000323
WO 2000-JP1777 W 20000323
US 2000-530495 A1 20000426

OTHER SOURCE(S): MARPAT 134:4946
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

10/ 075,073

AB Methods for prepn. of thienopyrimidines I (R1, R2 = H, OH, (un)substituted C1-4 alkoxy, C1-4 alkoxy-carbonyl or C1-4 alkyl; R3 = H, halo, OH or (un)substituted C1-4 alkoxy, n = 0-5, if n = 2 then two adjacent R3 may form C1-4 alkylenedioxy; R4 = H or C1-4 alkyl; R6 = (un)substituted C1-4 alkyl or a group of the formula Q wherein R5 is hydrogen or R4 and R5 may form heterocycle); or a pharmaceutically acceptable salt thereof, having excellent GnRH-antagonizing activity, were disclosed, as well as pharmaceutical compns. for treating sex hormone-dependent diseases. Thus, compd. II [R7 = MeONHCONH (III)] was prepd. by reacting the starting amine II (R7 = NH2) with N,N'-carbonyldiimidazole followed by O-methylhydroxylamine hydrochloride. The hydrochloride salt of III demonstrated an IC50 value of 0.0001 .mu.M against binding of 125I-leuprorelin at human GnRH receptors expressed in CHO cells.

IT **308831-61-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thienopyrimidines as gonadotropin releasing hormone antagonist)

RN 308831-61-0 CAPLUS

CN Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-1,2,3,4-tetrahydro-5-[[methyl(phenylmethyl)amino]methyl]-2,4-dioxo-3-phenylthieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 32 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:742096 CAPLUS
DOCUMENT NUMBER: 133:296325
TITLE: Preparation of xanthine derivatives and analogs as cell signaling inhibitors
INVENTOR(S): Klein, J. Peter; Klaus, Stephen J.; Kumar, Anil M.; Gong, Baoqing
PATENT ASSIGNEE(S): Cell Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061583	A1	20001019	WO 2000-US9139	20000407
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6100271	A	20000808	US 1995-483871	19950607
US 6103730	A	20000815	US 1995-486264	19950607
US 2002028823	A1	20020307	US 1999-288556	19990409
EP 1171442	A1	20020116	EP 2000-921774	20000407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541258	T2	20021203	JP 2000-610854	20000407

PRIORITY APPLN. INFO.:

US 1995-483871	A2	19950607
US 1995-486264	A2	19950607
US 1999-288556	A2	19990409
US 1994-199368	B2	19940218
US 1994-217051	B1	19940324
US 1998-8020	B2	19980116
WO 2000-US9139	W	20000407

OTHER SOURCE(S): MARPAT 133:296325

GI



I

AB Therapeutic compds. I [R1 = H, Me, (un)substituted C5-9-alkyl, C5-9-alkenyl, C5-9-alkynyl, C3-8-hydroxyalkyl, C3-8-alkoxy, C5-9-alkoxyalkyl; R2, R3 = H, halo, oxo, (un)substituted C1-20-alkyl, C1-20-hydroxyalkyl, C(1-20)thioalklyl, C1-20-alkylamino, C1-20-alkylaminoalkyl, C1-20-aminoalkyl, C1-20-aminoalkoxyalkenyl, C1-20-aminoalkoxyalkynyl, C1-20-diaminoalkyl, C1-20-triaminoalkyl, C1-20-tetraaminoalkyl, C5-15-aminotrialkoxyamino, C1-20-alkylamido, C1-20-alkylamidoalkyl, C1-20-amidoalkyl, C1-20-acetamidoalkyl, C1-20-alkenyl, C1-20-alkynyl, C3-8-alkoxyl, C1-11-alkoxyalkyl, and C1-20-dialkoxyalkyl; with the proviso that R1 .noteq. .omega.-1 secondary alc. substituted C5-8-alkyl; X, Y = NR3, R3 = C1-3-alkyl; Z = CR3, R3 = C1-3-alkyl; dashed lines are single or double bonds] pharmaceutically acceptable derivs. (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof are described. Thus, CT11495 [I; R1 = Me R2 = (CH2)4CH(OH)Me-(R), X = NMe, YZ= N:CH] was prepd., via N-alkylation of 1,7-dimethylxanthine (I; R1 = Me R2 = H, X = NMe, YZ= N:CH) with (R)-5-acetoxy-1-bromohexane followed by O-deacetylation. These novel heterocyclic compds. I having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations assocd. with disorders affected by Interleukin-12 ("IL-12") intracellular

10/ 075,073

signalling, such as, for example, Th1 cell-mediated disorders.

IT **301536-59-4P**, CT 12458
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(pn. of xanthine derivs. and analogs as cell signaling inhibitors)

RN 301536-59-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione, 3-[(5R)-5-hydroxyhexyl]-1,5,7-trimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:736052 CAPLUS

DOCUMENT NUMBER: 134:97065

TITLE: Kinetic analysis of novel multisubstrate analogue inhibitors of thymidine phosphorylase

AUTHOR(S): Balzarini, J.; Degreve, B.; Esteban-Gamboa, A.; Esnouf, R.; De Clercq, E.; Engelborghs, Y.; Camarasa, M.-J.; Perez-Perez, M.-J.

CORPORATE SOURCE: Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, B-3000, Belg.

SOURCE: FEBS Letters (2000), 483(2,3), 181-185
CODEN: FEBLAL; ISSN: 0014-5793

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A kinetic anal. was performed for the novel 1-(8-phosphonooctyl)-6-amino-5-bromouracil and 1-(8-phosphonooctyl)-7-deazaxanthine inhibitors of Escherichia coli thymidine (dThd) phosphorylase (TPase). The structure of the compds. was rationally designed based on the available crystal structure coordinates of bacterial TPase. These inhibitors reversibly inhibited TPase. Kinetic anal. revealed that the compds. inhibited TPase in a purely competitive or mixed fashion not only when dThd, but also when inorg. phosphate (Pi), was used as the variable substrate. In contrast, the free bases 6-amino-5-bromouracil and 7-deazaxanthine behaved as non-competitive inhibitors of the enzyme in the presence of variable Pi concns. while being competitive or mixed with respect to thymine as the natural substrate. Our kinetic data thus revealed that the novel 1-(8-phosphonooctyl)pyrimidine/purine derivs. are able to function as multisubstrate inhibitors of TPase, interfering at two different sites (dThd(Thy)- and phosphate-binding site) of the enzyme. To our knowledge, the described compds. represent the first type of such multisubstrate analog inhibitors of TPase; they should be considered as lead compds. for the development of mechanistically novel type of TPase inhibitors.

IT **39929-79-8**, 7-Deazaxanthine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **BIOL (Biological study)**
(kinetic anal. of novel multisubstrate analog inhibitors of thymidine

10/ 075,073

phosphorylase)
RN 39929-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 34 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:161290 CAPLUS
DOCUMENT NUMBER: 132:194389
TITLE: Preparation of thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones as immunosuppressants
INVENTOR(S): Bantick, John; Cooper, Martin; Perry, Matthew; Thorne, Philip
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012514	A1	20000309	WO 1999-SE1400	19990818
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2339664	AA	20000309	CA 1999-2339664	19990818
AU 9957677	A1	20000321	AU 1999-57677	19990818
EP 1107973	A1	20010620	EP 1999-944964	19990818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002523511	T2	20020730	JP 2000-567536	19990818
NZ 509809	A	20021126	NZ 1999-509809	19990818
US 6300334	B1	20011009	US 1999-402837	19991013

PRIORITY APPLN. INFO.: SE 1998-2895 A 19980828
WO 1999-SE1400 W 19990818
OTHER SOURCE(S): MARPAT 132:194389
GI

10/ 075,073



I



II

AB The title compds. (I) [wherein R = C(O)Ar1 or C(R4)(R5)Ar1;R1 and R2 = independently H, (cyclo)alkyl, alkenyl, or cycloalkylmethyl; R3 = H or XR9 or XAr2; R4 = H or alkyl; R5 = H or OH; R9 = Me optionally substituted by 1 or more CN, CO2H, alkoxycarbonyl, tetrazolyl, (un)substituted carboxyamido; R10 = H, alkyl, or R9; X = O, S(O)n, C(O)NR10, C(O)O, NHC(O)NR10, NHC(O)O, or SO2NR10; Ar1 = (un)substituted heteroaryl, Ar2 = (un)substituted Ph, pyridinyl, thienyl, pyridone, or pyridine N-oxide; n = 0-2] were prepd. as immunosuppressants. for the treatment of reversible obstructive airway diseases, such as asthma, bronchitis, and rhinitis. For example, II was formed in a 4-step sequence involving (1) N-addn. of 1-iodo-2-methylpropane to 6-chloro-3-methyl-1H-pyrimidine-2,4-(1H,3H)-dione, (2) thiolation of the chloro compd. with NaSH.H2O, (3) cycloaddn. of the 6-thioxopyrimidinedione with aq. ClCH2CHO, and (4) coupling of the thienopyrimidinedione with 1-methylbenzimidazole-2-carboxaldehyde. In a PMA/ionomycin-stimulated peripheral blood mononuclear cell (PBMC) proliferation assay, I exhibited IA50 values of < 1 .mu.M.

IT **259861-26-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compd.; prepn. of thieno[2,3-d]pyrimidine-2,4(1H,3H)-diones as immunosuppressants)

RN 259861-26-2 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 6-[hydroxy(1-methyl-1H-benzimidazol-2-yl)methyl]-3-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:96284 CAPLUS
DOCUMENT NUMBER: 132:305019
TITLE: Design, Synthesis, and Enzymatic Evaluation of Multisubstrate Analogue Inhibitors of Escherichia coli Thymidine Phosphorylase
AUTHOR(S): Esteban-Gamboa, Antonio; Balzarini, Jan; Esnouf, Robert; De Clercq, Erik; Camarasa, Maria-Jose;

10/ 075,073

	Perez-Perez, Maria-Jesus
CORPORATE SOURCE:	Instituto de Quimica Medica, C.S.I.C., Madrid, 28006, Spain
SOURCE:	Journal of Medicinal Chemistry (2000), 43(5), 971-983 CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER:	American Chemical Society
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A series of acyclic phosphonate derivs. of thymine has been synthesized and tested as multisubstrate analog inhibitors of Escherichia coli thymidine phosphorylase. The compds. synthesized include 1-(phosphonoalkyl)thymines with six to nine methylenes (1-4, resp.); 1-[(Z)-4-phosphonomethoxy-2-butenyl]thymine (5) and its Bu and 2,3-cis-dihydroxybutyl derivs. (6 and 7, resp.); 1-[(Z)-(4-(phosphonomethoxy)methoxy)-2-butenyl]thymine (8) and also its Bu and 2,3-cis-dihydroxybutyl analogs (9 and 10); and 1-[((Z)-4-(phosphonomethoxy)-2-butenoxy)methyl]thymine (11). Evaluation of these compds. against E. coli revealed significant enzymic inhibition by 2, 3, 4, 6, and 8 at a concn. of 1000 .mu.M, 3 and 4 being the most potent. Replacement of the thymine base in 3 by 6-amino-5-bromouracil and 7-deazaxanthine afforded compds. 12 and 13, which showed a pronounced improvement of TPase inhibition, comparable to 7-deazaxanthine. When inorg. phosphate was used as a variable substrate, compds. 12 and 13 displayed competitive kinetics with respect to phosphate, indicating a direct interaction of these compds. with the phosphate binding site. Also compds. 12 and 13 were found to be competitive inhibitors of TPase against thymidine as a variable substrate. These results are consistent with the compds. being multisubstrate analog inhibitors of E. coli TPase, and they represent the first example of such TPase inhibitors.

IT **39929-79-8P**, 7-Deazaxanthine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
(design, synthesis, and enzymic evaluation of multisubstrate analog inhibitors of thymidine phosphorylase)

RN 39929-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 36 OF 90 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER:	2000:68462 CAPLUS
DOCUMENT NUMBER:	132:107962
TITLE:	Preparation of piperazinylalkyl pyrimidinedione compounds selective for adrenoceptors
INVENTOR(S):	Meyer, Michael D.; Carroll, William A.
PATENT ASSIGNEE(S):	Abbott Laboratories, USA
SOURCE:	PCT Int. Appl., 52 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

10/ 075,073

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004027	A1	20000127	WO 1999-US15732	19990712
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6153614	A	20001128	US 1998-116376	19980716
CA 2336950	AA	20000127	CA 1999-2336950	19990712
EP 1095044	A1	20010502	EP 1999-933919	19990712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002520417	T2	20020709	JP 2000-560133	19990712

PRIORITY APPLN. INFO.: US 1998-116376 A 19980716
WO 1999-US15732 W 19990712

OTHER SOURCE(S): MARPAT 132:107962

GI



I



II



III

AB The title compds. [I; R1-R3 = halo, OH, NO2, etc.; R4 = II (wherein U taken together with the carbon atoms to which it is attached, forms a mono- or disubstituted 5-membered heterocycle having 4 carbon atoms, 2 double bonds, and one heteroatom selected from O, S, NH, N(alkyl), a mono or disubstituted 6-membered heterocycle contg. 3 double bonds and either 1, 2 or 3 N atoms, etc.; R5 = H, alkyl, alkenyl, etc.); n = 2-10] and their pharmaceutically acceptable salts, which are selective .alpha.-1D adrenoceptor antagonists and may be useful for treating disease states such as benign prostatic hyperplasia, hypertension, detrusor instability and incontinence, were prepd. E.g., a 3-step synthesis of III.MeSO3H which showed Ki of 0.213 nM against .alpha.1D binding (rat), was given.

IT **255713-48-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of piperazinylalkyl pyrimidinedione compds. selective for adrenoceptors)

10/ 075,073

RN 255713-48-5 CAPLUS
CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-5-phenyl-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 255713-47-4
CMF C25 H26 N4 O3 S



CM 2

CRN 75-75-2
CMF C H4 O3 S



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 37 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:760843 CAPLUS
DOCUMENT NUMBER: 132:151768
TITLE: Synthesis and molluscicidal activity of some new thieno[2,3-d]pyrimidinones and their related derivatives
AUTHOR(S): Hosni, Hanaa M.
CORPORATE SOURCE: Pesticide Chem. Dept., National Research centre, Cairo, Egypt
SOURCE: Egyptian Journal of Chemistry (1999), 42(5), 469-480
CODEN: EGJCA3; ISSN: 0449-2285
PUBLISHER: National Information and Documentation Centre
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Title compds. were prepd. from aminobithienylcarboxylate. The starting material and the thienopyrimidotriazole products showed excellent molluscicidal activity against Biomphalaria alexandrina.
IT **257870-39-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent)
(prepn. and molluscicidal activity of some new thieno[2,3-d]pyrimidinones and related compds.)
RN 257870-39-6 CAPLUS
CN Thieno[2,3-d]pyrimidin-4(1H)-one, 2,3-dihydro-3-methyl-5-(2-thienyl)-2-

10/ 075,073

thioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 38 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1999:659358 CAPLUS
DOCUMENT NUMBER: 131:286264
TITLE: Preparation of phenylsulfonamide derivatives as proteinase and aggrecanase inhibitors
INVENTOR(S): Kimura, Tomio; Miyazaki, Shoujiro; Ueda, Keiji; Tanzawa, Kazuhiko; Ushiyama, Shigeru; Takasaki, Wataru
PATENT ASSIGNEE(S): Sankyo Company, Limited, Japan
SOURCE: PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951572	A1	19991014	WO 1999-JP1751	19990402
W: AU, BR, CA, CN, CZ, HU, ID, IL, IN, KR, MX, NO, NZ, PL, PT, RU, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2327290	AA	19991014	CA 1999-2327290	19990402
AU 9929615	A1	19991025	AU 1999-29615	19990402
AU 756248	B2	20030109		
JP 2000319250	A2	20001121	JP 1999-96827	19990402
BR 9909398	A	20001226	BR 1999-9398	19990402
EP 1069110	A1	20010117	EP 1999-910822	19990402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 2000004949	A	20001107	NO 2000-4949	20001002

PRIORITY APPLN. INFO.: JP 1998-91819 A 19980403
JP 1999-53164 A 19990301
WO 1999-JP1751 W 19990402
OTHER SOURCE(S): MARPAT 131:286264
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. R5OR4SO2N(R3)CH(R2)COR1 [I; wherein R1 is H or NHOH; R2 is H, optionally substituted alkyl, cycloalkyl, or AR6 (wherein A is O, S(O)m, or alkylene optionally interrupted by N(R9); and R6 is a group represented by Q, Q1, Q2 wherein X is O, S, N(R10), or C(R11)(R12); Y is O, CO, S(O)n, N(R10), or C(R11)(R12); R7 and R8 each is H, alkyl, COOH, optionally substituted alkyl, etc.; R9, R10, R11, and R12 each is H,

alkyl, etc.; and m and n each is 0 to 2); R3 is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R4 is optionally substituted (hetero)arylene; and R5 is optionally substituted alkyl or optionally substituted (hetero)aryl], stereoisomers, pharmacol. acceptable salts, esters, or other derivs. thereof are prepd. and tested as matrix metalloproteinase-13 inhibitors and aggrecanase inhibitors. Thus, the title compd. II was prepd.

IT **246263-34-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)
(prepn. of phenylsulfonamides as proteinase and aggrecanase inhibitors)

RN 246263-34-3 CAPLUS

CN Thieno[2,3-d]pyrimidine-3(2H)-butanamide, 1,4-dihydro-N-hydroxy-5-methyl-.alpha.-[methyl[(4-phenoxyphenyl)sulfonyl]amino]-2,4-dioxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 39 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:795022 CAPLUS
DOCUMENT NUMBER: 130:38396
TITLE: Preparation of thieno[2,3-d]pyrimidinediones in treatment of reversible obstructive airways disease
INVENTOR(S): Cheshire, David; Cooke, Andrew; Cooper, Martin; Donald, David; Furber, Mark; Perry, Matthew; Thorne, Philip
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9854190	A1	19981203	WO 1998-SE935	19980518
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9876808	A1	19981230	AU 1998-76808	19980518
AU 723708	B2	20000907		
EP 991653	A1	20000412	EP 1998-924705	19980518
EP 991653	B1	20021016		

10/ 075,073

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

EE 9900539	A	20000615	EE 1999-539	19980518
EE 4018	B1	20030415		
BR 9809481	A	20000620	BR 1998-9481	19980518
JP 2002500666	T2	20020108	JP 1999-500565	19980518
AT 226205	E	20021115	AT 1998-924705	19980518
ES 2184270	T3	20030401	ES 1998-924705	19980518
US 6180635	B1	20010130	US 1998-117426	19980730
MX 9910911	A	20000430	MX 1999-10911	19991125
NO 9905810	A	20000127	NO 1999-5810	19991126
US 6342502	B1	20020129	US 2000-693896	20001023
US 6469014	B1	20021022	US 2001-977944	20011017
US 2002183337	A1	20021205		

PRIORITY APPLN. INFO.:

SE 1997-2001	A	19970528
WO 1998-SE935	W	19980518
US 1998-117426	A1	19980730
US 2000-693896	A1	20001023

OTHER SOURCE(S): CASREACT 130:38396; MARPAT 130:38396

GI



I

AB Title compds. [I; R is arylcarbonyl, aryl, arylalkyl; R1 and R2 are independently H, alkyl, alkenyl, cycloalkyl; X represents S(O)n, COO, NHCOO, etc.; R3 is Ph, pyridyl, CN, CO2H, SO2NH2, etc.; n is 0, 1, 2], stereoisomers, a pharmaceutically-acceptable salt or solvate are prepd. via cyclization and oxidn. processes. Title compds. were useful in the (prophylactic) treatment of autoimmune, inflammatory, proliferative and hyperproliferative diseases and immunol.-mediated diseases including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS).

IT **216685-02-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); **BIOL (Biological study)**; **BIOL (Biological study)**; PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of thienopyrimidinediones in treatment of reversible obstructive airway disease)

RN 216685-02-8 CAPLUS

CN Thieno[2,3-d]pyrimidine-2,4(1H,3H)-dione, 3-methyl-1-(2-methylpropyl)-6-(1-naphthalenylmethyl)- (9CI) (CA INDEX NAME)

10/ 075,073



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 40 OF 90 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1998:764730 CAPLUS
DOCUMENT NUMBER: 130:119563
TITLE: 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase
AUTHOR(S): Balzarini, Jan; Gamboa, Antonio Esteban; Esnouf, Robert; Liekens, Sandra; Neyts, Johan; De Clercq, Erik; Camarasa, Maria-Jose; Perez-Perez, Maria-Jesus
CORPORATE SOURCE: Rega Institute for Medical Research, K.U. Leuven, Louvain, B-3000, Belg.
SOURCE: FEBS Letters (1998), 438(1,2), 91-95
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB 7-Deazaxanthine (7DX) was identified as a novel inhibitor of thymidine (dThd) phosphorylase (TPase). It inhibited the TPase reaction in a concn.-dependent manner. At 1 mM, it almost completely prevented the TPase-catalyzed hydrolysis of dThd to thymine. The 50% inhibitory concn. (IC50) of 7DX was 40 .mu.M in the presence of 100 .mu.M of the natural substrate dThd. 7DX is also endowed with a marked inhibitory effect on angiogenesis. It significantly prevents neovascularization in the chicken chorioallantoic membrane during development. 7DX is the first purine deriv. shown to be a potent inhibitor of purified TPase and angiogenesis.

IT **39929-79-8**, 7-Deazaxanthine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); **BIOL (Biological study)**
(7-deazaxanthine prototype inhibitor of thymidine phosphorylase)
RN 39929-79-8 CAPLUS
CN 1H-Pyrrolo[2,3-d]pyrimidine-2,4(3H,7H)-dione (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 41 OF 90 CAPLUS COPYRIGHT 2003 ACS